Literature DB >> 22682917

The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly.

Patrick Petrossians1, Maria A Tichomirowa, Achile Stevenaert, Didier Martin, Adrian F Daly, Albert Beckers.   

Abstract

Acromegaly is a chronic rare disease associated with negative pathological effects on multiple systems and organs. We designed a new informatics tool to study data from patients with acromegaly, the Liege Acromegaly Survey (LAS). This relational database permits the inclusion of anonymous historical and prospective data on patients and includes pathophysiology, clinical features, responses to therapy and long term outcomes of acromegaly. We deployed the LAS in a validation study at a single center in order to study the characteristics of patients with acromegaly diagnosed at our center from 1970-2011. A total of 290 patients with acromegaly were included (147 males and 143 females). There was a linear relationship between age at diagnosis and the date of diagnosis, indicating that older patients are being diagnosed with acromegaly more frequently. A majority presented with macroadenomas (77.5%) and the median diameter was 14 mm. Patients with macroadenomas were significantly younger than patients with microadenomas (P=0.01). GH values at diagnosis decreased with the age of the patients (P=0.01) and there was a correlation between GH values and tumor size at diagnosis (P=0.02). No correlation existed between insulin-like growth factor 1 (IGF-1) levels and tumor characteristics. The prevalence of diabetes was 21.4% in this population and 41.0% had hypertension. The presence of hypertension and diabetes were significantly associated with one another (P<0.001). There was a linear relation between initial GH and IGF-1 levels at diagnosis and those obtained during SSA analog treatment and the lowest GH and IGF-1 values following SSA therapy were obtained in older patients (GH: P<0.001; IGF-1: P<0.001). The LAS is a new relational database that is feasible to use in the clinical research setting and permits ready pooling of anonymous patient data from multiple study sites to undertake robust statistical analyses of clinical and therapeutic characteristics.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682917     DOI: 10.1016/j.ando.2012.05.001

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  11 in total

1.  The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI.

Authors:  Carla-Liana Scânteie; Daniel-Corneliu Leucuţa; Cristina Ghervan
Journal:  Med Pharm Rep       Date:  2021-10-30

2.  Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.

Authors:  Fabio Tortora; Alberto Negro; Ludovica F S Grasso; Annamaria Colao; Rosario Pivonello; Alessandra Splendiani; Luca Brunese; Ferdinando Caranci
Journal:  Gland Surg       Date:  2019-09

3.  Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.

Authors:  Eva C Coopmans; Mark R Postma; Thalijn L C Wolters; Sebastiaan W F van Meyel; Romana Netea-Maier; André P van Beek; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 4.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

5.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

Review 6.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

7.  Approach to the Patient With Treatment-resistant Acromegaly.

Authors:  Eva C Coopmans; Aart J van der Lely; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

8.  Investigation of responsiveness to thyrotropin-releasing hormone in growth hormone-producing pituitary adenomas.

Authors:  Sang Ouk Chin; Sang Youl Rhee; Suk Chon; You-Cheol Hwang; In-Kyung Jeong; Seungjoon Oh; Sung-Woon Kim
Journal:  Int J Endocrinol       Date:  2013-11-21       Impact factor: 3.257

9.  Diabetic retinopathy in acromegaly.

Authors:  Said Azzoug; Farida Chentli
Journal:  Indian J Endocrinol Metab       Date:  2014-05

10.  Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly.

Authors:  Luciana Ansaneli Naves; Lara Benigno Porto; João Willy Corrêa Rosa; Luiz Augusto Casulari; José Wilson Corrêa Rosa
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.